| After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? |
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI. |
zacks.com |
2025-05-15 20:01:08 |
Czytaj oryginał (ang.) |
| Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim's growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development. Despite significant breakthroughs in the un. |
businesswire.com |
2025-05-14 12:30:00 |
Czytaj oryginał (ang.) |
| Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle |
The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials. The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America leads due to investment in R&D and numerous trials. |
globenewswire.com |
2025-05-14 11:36:00 |
Czytaj oryginał (ang.) |
| Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025 |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific and clinical studies highlighting the impact of AI and real-world data. |
businesswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Big Earnings Beats: 6 Stocks That Spiked After Reporting Results |
We're winding down earnings season, and the old Wall Street adage that “earnings drive stock prices” continues to prove true. |
247wallst.com |
2025-05-13 16:21:49 |
Czytaj oryginał (ang.) |
| These AI Stocks Posted Robust Results: Time to Buy? |
Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings. |
zacks.com |
2025-05-09 16:30:48 |
Czytaj oryginał (ang.) |
| Tempus AI Stock: Time to Double Down or Cut and Run? |
Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance. |
marketbeat.com |
2025-05-08 11:46:53 |
Czytaj oryginał (ang.) |
| Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals |
JP Morgan analyst Rachel Vatnsdal reiterated the Neutral rating on Tempus AI, Inc. TEM on Wednesday, with a price forecast of $55. |
benzinga.com |
2025-05-07 20:24:37 |
Czytaj oryginał (ang.) |
| Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript |
Tempus AI, Inc. (NASDAQ:TEM ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Liz Krutoholow – Vice President-Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Ryan MacDonald – Needham & Company Mark Schappel – Loop Capital Subbu Nambi – Guggenheim Daniel Brennan – TD Cowen Mark Massaro – BTIG Michael Ryskin – Bank of America Rachel Vatnsdal – JPMorgan Dan Arias – Stifel Operator Good day everyone. And thank you for standing by. |
seekingalpha.com |
2025-05-07 00:18:13 |
Czytaj oryginał (ang.) |
| Tempus Reports First Quarter 2025 Results |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic. |
businesswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect |
Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today. |
247wallst.com |
2025-05-06 13:41:52 |
Czytaj oryginał (ang.) |
| Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients' electronic health records. Notetaker complements Tempus'. |
businesswire.com |
2025-05-05 12:30:00 |
Czytaj oryginał (ang.) |
| Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. |
When it comes to shares of Tempus AI (TEM 0.31%), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this. |
fool.com |
2025-05-02 12:58:00 |
Czytaj oryginał (ang.) |
| Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the T. |
businesswire.com |
2025-05-01 12:30:00 |
Czytaj oryginał (ang.) |
| Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers,. |
businesswire.com |
2025-04-29 12:30:00 |
Czytaj oryginał (ang.) |
| Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? |
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up. |
zacks.com |
2025-04-28 20:00:41 |
Czytaj oryginał (ang.) |
| Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic de. |
businesswire.com |
2025-04-28 12:30:00 |
Czytaj oryginał (ang.) |
| Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment an. |
businesswire.com |
2025-04-25 12:30:00 |
Czytaj oryginał (ang.) |
| Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? |
Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI's de-identified oncology data. |
zacks.com |
2025-04-24 20:00:37 |
Czytaj oryginał (ang.) |
| Tempus to Report First Quarter 2025 Financial Results on May 6 |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible. |
businesswire.com |
2025-04-24 12:30:00 |
Czytaj oryginał (ang.) |
| 5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More |
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care. |
zacks.com |
2024-12-30 10:31:10 |
Czytaj oryginał (ang.) |
| Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought |
Cathie Wood's aggressive growth style of investing may have fallen flat earlier this year, but the co-founder, CEO, and ace stock picker at Ark Invest has been on a roll lately. Ark's most popular exchange-traded fund has soared 25% over the past three months and 36% over the past six months. |
fool.com |
2024-12-29 10:15:00 |
Czytaj oryginał (ang.) |
| Tempus AI Stock Plunges 28.9% in Three Months: What's Next? |
TEM is enhancing its offerings and expanding the breadth of products and services to improve patient care. However, macro challenges are likely to hurt its performance. |
zacks.com |
2024-12-24 14:31:08 |
Czytaj oryginał (ang.) |
| Tempus AI: A Potential Double-Bagger After Recent Pullback |
In mid-August, around two months after Tempus AI's NASDAQ: TEM initial public offering (IPO), the stock was up a marvelous 93%. However, shares have experienced wild volatility and are now 8% below their opening price of $37 as of the Dec. 18 close. |
marketbeat.com |
2024-12-20 10:45:00 |
Czytaj oryginał (ang.) |
| Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions |
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreement with Avalon, Tempus is a participating provider with BCBS North Carolina, BCBS South Carolina, BCBS Vermont, Capital Blu. |
businesswire.com |
2024-12-18 10:30:00 |
Czytaj oryginał (ang.) |
| Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays |
Tempus AI has strong long-term potential in healthcare technology, despite recent stock volatility due to lock-up period expiration and insider selling. The company's innovative "Intelligent Diagnostics" leverages generative AI and a vast proprietary dataset to drive personalized treatment options, positioning it as a leader in precision medicine. Financially, Tempus shows robust revenue growth but remains unprofitable; recent acquisitions and ongoing investments aim to strengthen its market position and path to profitability. |
seekingalpha.com |
2024-12-18 00:42:40 |
Czytaj oryginał (ang.) |
| New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. ECG-AF is one of just a few FDA-authorized medical technologies in the country to be impacted by the new CMS decision, and this milestone all. |
businesswire.com |
2024-12-17 10:30:00 |
Czytaj oryginał (ang.) |
| Tempus AI: Why I'm Buying This AI Stock |
Tempus AI's strategic acquisitions and partnerships, including Ambry Genetics and a JV with SoftBank, bolster its growth and competitive edge in AI health tech. The revenue growth and gross margins for Tempus AI's Data & Services division position Tempus AI for significant future profitability and cash flow. AI-driven automation and advanced machine learning algorithms enhance operational efficiency, reducing costs and accelerating data analysis for better client insights. |
seekingalpha.com |
2024-12-08 08:56:58 |
Czytaj oryginał (ang.) |
| Will Ambry Genetics Acquisition Drive Tempus AI's Prospects? |
TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine. |
zacks.com |
2024-11-25 16:25:25 |
Czytaj oryginał (ang.) |
| Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at the conference on Tuesday, December 3, 2024, at 3:00 p.m. ET. About Tempus Tempus is a technology company advancing precision medic. |
businesswire.com |
2024-11-25 10:30:00 |
Czytaj oryginał (ang.) |
| The Big 3: CRWD, CVNA, TEM |
@ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatility when it comes to Tempus AI (TEM). |
youtube.com |
2024-11-22 14:14:38 |
Czytaj oryginał (ang.) |
| Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation |
Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecular data library, advanced AI algorithms, and strategic partnerships with pharmaceutical giants like Merck and BioNTech. Despite profitability concerns and high cash burn, Tempus AI's revenue growth, strategic acquisitions, and unique data assets create a compelling long-term investment. |
seekingalpha.com |
2024-11-12 18:56:02 |
Czytaj oryginał (ang.) |
| Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DN. |
businesswire.com |
2024-11-11 10:30:00 |
Czytaj oryginał (ang.) |
| Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript |
Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Rachel Vatnsdal – JPMorgan Michael Ryskin – Bank of America Daniel Brennan – TD Cowen Ryan MacDonald – Needham Andrew Brackmann – William Blair Operator Thank you for standing by. My name is Briana, and I will be your conference operator today. |
seekingalpha.com |
2024-11-09 07:10:01 |
Czytaj oryginał (ang.) |
| Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. “Presenting our latest research is a vital opportunity to showcase the advancements Tempus is making in harnessing the power of data and AI to drive im. |
businesswire.com |
2024-11-08 10:30:00 |
Czytaj oryginał (ang.) |
| Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (. |
businesswire.com |
2024-11-07 18:30:00 |
Czytaj oryginał (ang.) |
| Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates |
TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level. |
zacks.com |
2024-11-05 13:30:30 |
Czytaj oryginał (ang.) |
| Tempus to Report Third Quarter 2024 Financial Results on November 4 |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus. |
businesswire.com |
2024-11-03 22:06:00 |
Czytaj oryginał (ang.) |
| Tempus: Attempting To Lead The AI Revolution In Healthcare |
Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutionize healthcare diagnostics, a space which has large gaps and is relatively untapped. Despite an impressive revenue profile and a burgeoning data licensing vertical, TEM remains a long way off profitability and faces high operating cash burn and SG&A expenses. |
seekingalpha.com |
2024-10-29 15:47:46 |
Czytaj oryginał (ang.) |
| Tempus to Report Third Quarter 2024 Financial Results on November 7 |
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast w. |
businesswire.com |
2024-10-24 12:30:00 |
Czytaj oryginał (ang.) |